Test vaccine and radiation with chemotherapy for new brain tumor
Part of Cancer clinical trials.
This trial studies a gene-based treatment (HSV-tk) given with radiation and chemotherapy for people newly diagnosed with glioblastoma or anaplastic astrocytoma. It may help the new brain tumor respond better to standard treatments, though risks and benefits are still being tested.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new brain tumor diagnosis of glioblastoma or anaplastic astrocytoma confirmed by biopsy
- Your scans must not show multiple large separate tumor areas (or brainstem involvement), except some specific leptomeningeal cases
- You should be able to expect treatment for at least 12 weeks (life expectancy ≥ 12 weeks)
- You must not have had prior radiation, chemotherapy, or gene/vector or similar immune treatments in the last few weeks
- Your blood counts and organ labs must be strong enough (blood and liver/kidney tests meet set limits)
- You must be willing to return for biopsies during the study and follow birth-control rules if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a “suicide gene” therapy delivered by a virus along with radiation for adults whose high-grade brain tumor has come back or grown again. The goal is to see if the treatment is safe and can help control the tumor.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This trial tests a new injection called VRT106 for people whose glioblastoma (a brain tumor) has come back or is growing. It uses a virus that may help the immune system attack the tumor. This study is for those who have not had a similar virus or gene therapy before.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.